Skip to content

The clinical and pharmacological research of Jianpiliqi granule in the treatment of spleen deficiency and qi stagnation of functional dyspepsia

The clinical and pharmacological research of Jianpiliqi granule in the treatment of spleen deficiency and qi stagnation of functional dyspepsia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012471
Enrollment
Unknown
Registered
2017-08-25
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

functional dyspepsia

Interventions

Group B:Placebo
Group A:Jianpiliqi granule

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 65 years old; 2. fulfill the diagnostic criteria of Functional dyspepsia in Rome IV; 3. The main symptom score was above II; 4. fulfill the syndrome of Spleen deficiency and qi stagnation; 5. Voluntarily signed informed consent; 6. Nearly a year underwent endoscopy, Check the results were no obvious abnormalities or Chronic superficial gastritis.

Exclusion criteria

Exclusion criteria: 1. The digestive system disease(Peptic ulcer, reflux esophagitis, erosive gastritis (grade 2 or more), atrophic gastritis, digestive tract tumors, gastrointestinal bleeding, liver, gallbladder, spleen, pancreas diseases, intestinal obstruction, inflammatory bowel disease); 2. Systemic disease affecting digestive tract motility; 3. Combined with severity heart, lung, central nervous system, liver, gallbladder,pancreatic organic disease. Liver disease activity or liver dysfunction, Kidney disease or renal insufficiency; 4. Past history of abdominal surgery (appendectomy and cesarean section except); 5. lactating or pregnant women,Planning for pregnancy; 6. Disabled persons as prescribed by law; 7. Alcohol, drugs or illicit drugs history; 8. use Other prokinetic drugs, Mucous membrane protective agent or Acid inhibitor, Antidepressant, anxiolytics; 9. be allergy to the trial drug,Allergic constitution; 10. lactating or pregnant women, Planning for pregnancy; 11. The researchers believe that patients are not suitable.

Design outcomes

Primary

MeasureTime frame
Symptom curative;Treatment effect;

Secondary

MeasureTime frame
FDQOL scores change after of treatmen;HAMA scores change after of treatmen;HAMD scores change after of treatmen;gastric emptying rate;Curative effect of TCM Syndrome;

Countries

China

Contacts

Public ContactHuang Suiping

Guangdong Provincial Hosptial of Chinese Medicine

gzdoctorhsp@126.com+86 13711026653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026